Experience of using sibutramine in combination with microcrystalline cellulose in clinical practice

For many years, interest in the issue of obesity has not faded, as obesity is now one of the most common pathologies in the world that directly affects quality of life and lifespan. Even a slight weight loss (5-10% of baseline values) in obese patients is known to improve metabolism and reduce the risk of a range of comorbidities. The article reflects the importance of comprehensive treatment of obesity, presents positive experience of using Reduxin (sibutramine in combination with microcrystalline cellulose) to reduce body weight and risk factors for cardiovascular disease in a specific clinical example in a patient with exogenous-constitutional obesity and eating disorders. The case of obesity in a young man of 24 years old is presented, when other components of the metabolic syndrome (except for arterial hypertension) were not formed. Thus, following the results of 24-week complex treatment, clinically significant reduction of body weight (by 21.7% of initial values) was observed in the patient. The data of psychological researches have shown that the patient has no increase of anxiety and depression level during treatment, but at the same time the indicators of quality of life according to the results of health questionnaire testing have improved. This clinical case corresponds to the results of the PrimaVera program and demonstrates that weight loss during sibutramine therapy in combination with microcrystalline cellulose has a positive impact on the overall health and emotional status of patients and leads to improved quality of life. Therefore, successful treatment of obesity and the maintenance of other outcomes are key to preventing cardiovascular disease.

1. Whitlock G., Lewington S., Sherliker P., Clarke R., Emberson J., Halsey J., Qizilbash N., Collins R., Peto R. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083-1096. doi: 10.1016/S0140-6736(09)60318-4.

2. Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18(4):317-332. doI: 10.1111/dom.12596.

3. Loveman E., Frampton G.K., Shepherd J., Picot J., Cooper K., Bryant J., Welch K., Clegg A. The clinical effectiveness and cost-effectiveness of longterm weight management schemes for adults: a systematic review. Health Technol Assess. 2011;15(2):1-182. doi: 10.3310/hta15020.

4. Rahmouni K., Correia M.L., Haynes W.G., Mark A.L. Obesity-associated hypertension: new insights into mechanisms. Hypertension. 2005;45(1):9-14. doi: 10.1161/01.HYP.0000151325.83008.b4.

5. Dedov I.I., Melnichenko G.A., Shestakova M.V., Troshina E.A., Mazurina N.V., Shestakova E.A., Yashkov Yu.I., Neimark A.E. et al. Morbid obesity treatment in adults. Obesity and metabolism. 2018;15(1):53-70. (In Russ.) doi: 10.14341/omet2018153-70.

6. Logvinova O.V., Galieva M.O., Mazurina N.V., Troshina E.A. Logvinova OV, Galieva MO, Mazurina NV, Troshina EA. The place of centralacting drugs in the algorithms of treatment of primary obesity. Obesity and metabolism. 2017;14(2):18-23. (In Russ.) doi: 10.14341/omet2017218-23.

7. Fadeeva M.I., Savelyeva L.V., Golubkina Yu.Yu., Morozova E.V., Motkova S.I. Correction of eating disorders in obese patients. Ehndokrinologiya: novosti, mneniya, obuchenie = Endocrinology: News, Opinions, Training. 2018;7(2):51–59. (In Russ.) doi: 10.24411/2304-9529-2018-12005.

8. Dedov I.I., Mel’nichenko G.A., Romantsova T.I. The strategy of obesity management: the results of All-Russian observational program «Primavera». Obesity and metabolism. 2016;13(1):36-44. (In Russ.) doi: 10.14341/omet2016136-44

9. Voznesenskaya T.G. Obesity. Chapter 9. Typology of PP disorders and emotional-personality disorders in primary obesity and their correction. In the book: Obesity: etiology, pathogenesis, clinical aspects. Moscow: Medical Information Agency; 2004:236–256. (In Russ.)